ADCT 402 - ADC Therapeutics

Drug Profile

ADCT 402 - ADC Therapeutics

Alternative Names: ADCT-402

Latest Information Update: 24 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ADC Therapeutics
  • Class Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma; Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute lymphoblastic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 23 Oct 2017 ADC Therapeutics plans registrational trials for ADCT 402 in 2018
  • 16 Jun 2017 Interim efficacy and safety data from a part I of phase I/II trial in non-Hodgkin’s lymphoma released by ADC Therapeutics
  • 09 Jun 2017 ADCT 402 receives Orphan Drug status for Diffuse large B cell lymphoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top